HUP0000065A2 - Olanzapin-dihidrát D és az azt tartalmazó gyógyszerkészítmények - Google Patents

Olanzapin-dihidrát D és az azt tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0000065A2
HUP0000065A2 HU0000065A HUP0000065A HUP0000065A2 HU P0000065 A2 HUP0000065 A2 HU P0000065A2 HU 0000065 A HU0000065 A HU 0000065A HU P0000065 A HUP0000065 A HU P0000065A HU P0000065 A2 HUP0000065 A2 HU P0000065A2
Authority
HU
Hungary
Prior art keywords
olanzapine
dihydrate
same
pharmaceutical compositions
compositions containing
Prior art date
Application number
HU0000065A
Other languages
English (en)
Inventor
Samuel D. Larsen
John R. Nichols
Susan M. Reutzel
Gregory A. Stephenson
Original Assignee
Eli Lilly And Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21832112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0000065(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Co. filed Critical Eli Lilly And Co.
Publication of HUP0000065A2 publication Critical patent/HUP0000065A2/hu
Publication of HUP0000065A3 publication Critical patent/HUP0000065A3/hu
Publication of HU226167B1 publication Critical patent/HU226167B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány tárgyát stabil kristályős dihidrát D őlanzapin (2-metil4-(4-metil-1-piperazinil)-10H-tienő[2,3-b][1,5]benződiazepin) pőlimőrfképezi. A találmány szerinti dihidrát D őlanzapin pőlimőrfbólgyógyászatilag megfelelő stabil vizes készítmények állíthatók elő. Atalálmány tárgyáhőz tartőznak ezen kívül a fenti dihidrát D őlanzapinttartalmazó gyógyászati készítmények is, valamint kezelési eljárásemlősök pszichőtikűs állapőtainak kezelésére, amely célra a fentigyógyászati készítményeket adják. A pszichőtikűs állapőtők közülemlítik meg példáűl a skizőfréniát, és a bélműködés rendellenességeit. ŕ
HU0000065A 1996-09-23 1997-09-18 Olanzapin-dihidrát D, elõállítása és az azt tartalmazó gyógyszerkészítmények HU226167B1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2648696P 1996-09-23 1996-09-23
PCT/US1997/016586 WO1998011893A1 (en) 1996-09-23 1997-09-18 Olanzapine dihydrate d

Publications (3)

Publication Number Publication Date
HUP0000065A2 true HUP0000065A2 (hu) 2000-06-28
HUP0000065A3 HUP0000065A3 (en) 2000-11-28
HU226167B1 HU226167B1 (hu) 2008-05-28

Family

ID=21832112

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0000065A HU226167B1 (hu) 1996-09-23 1997-09-18 Olanzapin-dihidrát D, elõállítása és az azt tartalmazó gyógyszerkészítmények

Country Status (35)

Country Link
US (1) US6251895B1 (hu)
EP (1) EP0831097B1 (hu)
JP (1) JP2001500878A (hu)
KR (1) KR100516088B1 (hu)
CN (1) CN1146567C (hu)
AR (1) AR009801A1 (hu)
AT (1) ATE221074T1 (hu)
AU (1) AU720366B2 (hu)
BR (1) BR9711541A (hu)
CA (1) CA2266444C (hu)
CO (1) CO4900057A1 (hu)
CZ (1) CZ299247B6 (hu)
DE (1) DE69714165T2 (hu)
DK (1) DK0831097T3 (hu)
EA (1) EA001881B1 (hu)
EG (1) EG23815A (hu)
ES (1) ES2180899T3 (hu)
HK (1) HK1009809A1 (hu)
HU (1) HU226167B1 (hu)
ID (1) ID21924A (hu)
IL (1) IL128956A0 (hu)
MY (1) MY125467A (hu)
NO (1) NO323979B1 (hu)
NZ (1) NZ334346A (hu)
PE (1) PE110298A1 (hu)
PL (1) PL194074B1 (hu)
PT (1) PT831097E (hu)
RS (1) RS49597B (hu)
SI (1) SI0831097T1 (hu)
SV (1) SV1997000079A (hu)
TR (1) TR199900639T2 (hu)
TW (1) TW518335B (hu)
UA (1) UA56184C2 (hu)
WO (1) WO1998011893A1 (hu)
ZA (1) ZA978512B (hu)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
EA002580B1 (ru) * 1998-09-30 2002-06-27 Эли Лилли Энд Компани Готовая препаративная форма 2-метил-тиено-бензодиазепина
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
WO2001047933A1 (en) * 1999-12-28 2001-07-05 Cipla Limited New polymorphic forms of olanzapine
BR0114031A (pt) * 2000-08-31 2003-09-09 Reddy S Lab Ltd Processo para a preparação de hidratos de olanzapina e sua conversão em formas cristalinas de olanzapina
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
WO2003037903A1 (en) * 2001-10-29 2003-05-08 Dr. Reddy's Laboratories Ltd. Olanzapine dihydrate-ii a process for its preparation and use thereof
WO2003101997A1 (en) * 2002-05-31 2003-12-11 Geneva Pharmaceuticals, Inc. Process of preparation of olanzapine form i
SI21270A (sl) 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2004058773A1 (en) * 2002-12-24 2004-07-15 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
EP1684734A2 (en) * 2003-11-18 2006-08-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
WO2005070938A1 (en) 2004-01-27 2005-08-04 Synthon B.V. Stable salts of olanzapine
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20080009481A1 (en) * 2004-07-14 2008-01-10 Shasun Chemicals And Drugs Limited Process For Making Form I Of Olanzapine
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US7829700B2 (en) 2004-09-06 2010-11-09 Shasun Chemicals And Drugs Limited Process for preparation of a pharmaceutically pure polymorphic form I of Olanzapine
NZ553804A (en) 2004-09-29 2010-07-30 Bayer Schering Pharma Ag Thermodynamically stable form of bay 43-9006 tosylate
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US7910577B2 (en) * 2004-11-16 2011-03-22 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
ATE511512T1 (de) 2005-01-05 2011-06-15 Lilly Co Eli Olanzapinpamoat-dihydrat
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US8551986B2 (en) * 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
US7834176B2 (en) * 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
WO2009019205A1 (en) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
AU2008359725A1 (en) * 2008-07-24 2010-01-28 Handa Pharmaceuticals, Llc Stabilized atypical antipsychotic formulation
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20110067096A (ko) 2008-09-10 2011-06-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 및 관련 상태를 치료하기 위한 병용 요법
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
BR112012012641A2 (pt) 2009-11-27 2020-08-11 Boehringer Ingelheim International Gmbh TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
EP3366304B1 (en) 2010-06-24 2020-05-13 Boehringer Ingelheim International GmbH Diabetes therapy
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
WO2013010964A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
JP2016027003A (ja) * 2012-11-20 2016-02-18 大蔵製薬株式会社 長期間安定なオランザピンの水性医薬製剤
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
EP3468562A1 (en) 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302716A (en) * 1986-01-16 1994-04-12 Schering Corporation Fused benzazepines
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
NZ247703A (en) * 1992-05-29 1995-07-26 Lilly Industries Ltd Thienobenzdiazepine derivatives and medicaments thereof
NZ289619A (en) 1994-06-28 1998-12-23 Grace W R & Co Bag with patches, the patches having overhang regions which are adhered together
US5631250A (en) * 1995-03-24 1997-05-20 Eli Lilly And Company Process and solvate of 2-methyl-thieno-benzodiazepine
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
EP0733368A1 (en) * 1995-03-24 1996-09-25 Eli Lilly And Company Granule fomulation for olanzapine

Also Published As

Publication number Publication date
NO991339L (no) 1999-03-19
ZA978512B (en) 1999-03-23
CN1146567C (zh) 2004-04-21
UA56184C2 (uk) 2003-05-15
HK1009809A1 (en) 1999-06-11
ATE221074T1 (de) 2002-08-15
AU4424197A (en) 1998-04-14
EA199900325A1 (ru) 1999-08-26
PT831097E (pt) 2002-10-31
RS49597B (sr) 2007-06-04
EG23815A (en) 2007-08-19
NO991339D0 (no) 1999-03-19
CA2266444A1 (en) 1998-03-26
AU720366B2 (en) 2000-06-01
EP0831097A3 (en) 1998-04-29
US6251895B1 (en) 2001-06-26
PL194074B1 (pl) 2007-04-30
NO323979B1 (no) 2007-07-30
AR009801A1 (es) 2000-05-03
CZ98999A3 (cs) 1999-08-11
TR199900639T2 (xx) 1999-06-21
EP0831097B1 (en) 2002-07-24
HU226167B1 (hu) 2008-05-28
SV1997000079A (es) 1999-01-13
TW518335B (en) 2003-01-21
EA001881B1 (ru) 2001-10-22
WO1998011893A1 (en) 1998-03-26
KR20000048519A (ko) 2000-07-25
PE110298A1 (es) 1999-01-18
DE69714165D1 (de) 2002-08-29
EP0831097A2 (en) 1998-03-25
ES2180899T3 (es) 2003-02-16
CO4900057A1 (es) 2000-03-27
CN1234738A (zh) 1999-11-10
BR9711541A (pt) 1999-08-24
KR100516088B1 (ko) 2005-09-22
NZ334346A (en) 2000-05-26
SI0831097T1 (en) 2003-02-28
IL128956A0 (en) 2000-02-17
DK0831097T3 (da) 2002-09-02
CA2266444C (en) 2007-01-09
ID21924A (id) 1999-08-12
JP2001500878A (ja) 2001-01-23
HUP0000065A3 (en) 2000-11-28
DE69714165T2 (de) 2003-01-23
YU15499A (sh) 2000-03-21
PL332541A1 (en) 1999-09-13
CZ299247B6 (cs) 2008-05-28
MY125467A (en) 2006-08-30

Similar Documents

Publication Publication Date Title
HUP0000065A2 (hu) Olanzapin-dihidrát D és az azt tartalmazó gyógyszerkészítmények
HUP9802824A2 (hu) Egy 2-metil-tieno-benzodiazepin-származék kristályformái és eljárás azok előállítására
HUP0004534A2 (hu) Olanzapint tartalmazó gyógyszerkészítmény
HUP9902056A2 (hu) Fuzionált 1,2,4-tiadiazin- és fuzionált 1,4-tiazinszármazékok, azok előállítása és alkalmazása
IL161833A0 (en) Pharmaceutical compositions and usethereof for thetreatment of psychotic diseases
CA2272705A1 (en) Fused bicyclic pyrimidine derivatives
HUP0101246A3 (en) Novel galenic formulations of meloxicam for oral administration and process for their preparation
TW372872B (en) Thieno[1,5]benzodiazepine use
AR014854A1 (es) POLIMORFO CRISTALINO DEL HIDROGENOSULFATO DE CLOPIDROGREL (FORMA2) (+)-(S)-ALFA-(2-CLOROFENIL)-4,5,6,7-TETRAHIDROTIENO[3,2-C]PIRIDINIL-5-ACETATO DE METILO ,PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIoN FARMACÉUTICA QUE LO CONTIENE
AR243891A1 (es) Procedimiento de preparacion del enantiomero dextrogiro del alfa-(tetrahidro-4,5,6,7-tieno)(3,2-c)-piridil-5-)-(cloro-2-fenil)-acetato de metilo.
IL113967A (en) Piperazine derivatives pharmaceutical compositions containing them and their preparation
HUP0000664A3 (en) Azinyloxy, and phenoxy-diaryl-carboxylic acid derivatives, their preparation and use of them for producing pharmaceutical compositions
PT84899A (en) Process for the preparation of pharmaceutical compositions containing ?-phenyl-1,2-benzisoselenazol-3(2h)-one for the treatment of skin diseases
HUT74187A (en) 3-phenyl-izoquinolin-(2h)-one derivatives, process for producing them and use of them for producing pharmaceutical compositions
HUP0103636A2 (hu) 2-Metil-tieno-benzodiazepin készítmény és alkalmazása
HUP0001385A3 (en) Pro-drugs and derivatives of camptothecin, process for their preparation, use thereof and pharmaceutical compositions containing them
NZ240406A (en) Substituted indolizino [1,2-b]quinolin-9(11h)-one derivatives, pharmaceutical formulations and use as antiviral agents
HUP9801993A3 (en) Ascomycin derivatives and their use for preparation of pharmaceutical compositions, process for their preparation and pharmaceutical compositions containing them
IL118162A0 (en) Nanoparticles for oral administration of pharmaceutical agents of low solubility
HUP0103004A3 (en) Substituted imidazo[1,2a]azines as selective inhibitors of cox-2, process for their preparation and pharmaceutical compositions containing them
HUP9901038A3 (en) Pyrido[2,3-b]pyrazine derivatives, pharmaceutical compositions containing these compounds, process for the preparation and use of the ingredients and compositions
HUP0301082A2 (hu) Új polimorf olanzapine hidroklorid sók, eljárás ezek előállítására, az ezeket tartalmazó gyógyászati készítmények és felhasználásuk
PL328123A1 (en) Derivatives of banzo[c]quinolysine and method of obtaining them
HUP0003394A2 (hu) Pirido[2,3-b][1,5]benzodiazepin-származékok, alkalmazásuk, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
TNSN01001A1 (fr) NOUVELLES PYRAZOLO [4,3-e] DIAZEPINES SUBSTITUEES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees